Understanding how cystic fibrosis mutations disrupt CFTR function: From single molecules to animal models

详细信息    查看全文

• 作者：Yiting Wang ; Joe A. Wrennall ; Zhiwei Cai ; Hongyu Li ; David N. Sheppard ; ^{D.N.Sheppard@bristol.ac.uk" class="auth_mail}
• 关键词：ASL ; airway surface liquid ; CF ; cystic fibrosis ; CFTR ; cystic fibrosis transmembrane conductance regulator ; ECL ; extracellular loop ; ICL ; intracellular loop ; M ; transmembrane segment ; MSD ; membrane-spanning domain ; NBD ; nucleotide-binding domain ; PI ; pancreatic insufficiency ; PS ; pancreatic sufficiency ; PTC ; premature termination codon ; RD ; regulatory domain
• 刊名：The International Journal of Biochemistry and Cell Biology
• 出版年：July 2014
• 年：2014
• 卷：52
• 期：Complete
• 页码：47-57
• 全文大小：2616 K

文摘

Defective epithelial ion transport is the hallmark of the life-limiting genetic disease cystic fibrosis (CF). This abnormality is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR), the ATP-binding cassette transporter that functions as a ligand-gated anion channel. Since the identification of the CFTR gene, almost 2000 disease-causing mutations associated with a spectrum of clinical phenotypes have been reported, but the majority remain poorly characterised. Studies of a small number of mutations including the most common, F508del-CFTR, have identified six general mechanisms of CFTR dysfunction. Here, we review selectively progress to understand how CF mutations disrupt CFTR processing, stability and function. We explore CFTR structure and function to explain the molecular mechanisms of CFTR dysfunction and highlight new knowledge of disease pathophysiology emerging from large animal models of CF. Understanding CFTR dysfunction is crucial to the development of transformational therapies for CF patients.

This article is part of a Directed Issue entitled: Cystic Fibrosis: From o-mics to cell biology, physiology, and therapeutic advances.